Selected research
Market Structure
Global Maternal Pertussis Vaccine for Newborn Protection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Maternal Pertussis Vaccine for Newborn Protection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Maternal Pertussis Vaccine for Newborn Protection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Maternal Pertussis Vaccine for Newborn Protection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Maternal Pertussis Vaccine for Newborn Protection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Maternal Pertussis Vaccine for Newborn Protection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Maternal Pertussis Vaccine for Newborn Protection include Zhifei Biological, Walvax, Minhai Biological, GlaxoSmithKline, Sanofi Pasteur and Intravacc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Maternal Pertussis Vaccine for Newborn Protection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Maternal Pertussis Vaccine for Newborn Protection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Maternal Pertussis Vaccine for Newborn Protection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Maternal Pertussis Vaccine for Newborn Protection market size, projected growth trends, production technologies, key applications, and end-use industries.
Maternal Pertussis Vaccine for Newborn Protection Segment by Company
Zhifei Biological
Walvax
Minhai Biological
GlaxoSmithKline
Sanofi Pasteur
Intravacc
Maternal Pertussis Vaccine for Newborn Protection Segment by Type
Whole-cell Pertussis Vaccine
Acellular Pertussis Vaccine
Maternal Pertussis Vaccine for Newborn Protection Segment by Application
Hospital
Centers for Disease Control and Prevention
Others
Maternal Pertussis Vaccine for Newborn Protection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Maternal Pertussis Vaccine for Newborn Protection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Maternal Pertussis Vaccine for Newborn Protection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Maternal Pertussis Vaccine for Newborn Protection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Maternal Pertussis Vaccine for Newborn Protection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Maternal Pertussis Vaccine for Newborn Protection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Maternal Pertussis Vaccine for Newborn Protection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Maternal Pertussis Vaccine for Newborn Protection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Whole-cell Pertussis Vaccine
- Acellular Pertussis Vaccine
Applications
- Hospital
- Centers for Disease Control and Prevention
- Others
Companies covered
- Zhifei Biological
- Walvax
- Minhai Biological
- GlaxoSmithKline
- Sanofi Pasteur
- Intravacc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Maternal Pertussis Vaccine for Newborn Protection Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Maternal Pertussis Vaccine for Newborn Protection Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Maternal Pertussis Vaccine for Newborn Protection Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Maternal Pertussis Vaccine for Newborn Protection Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Maternal Pertussis Vaccine for Newborn Protection Market Dynamics
- 2.1 Maternal Pertussis Vaccine for Newborn Protection Industry Trends
- 2.2 Maternal Pertussis Vaccine for Newborn Protection Industry Drivers
- 2.3 Maternal Pertussis Vaccine for Newborn Protection Industry Opportunities and Challenges
- 2.4 Maternal Pertussis Vaccine for Newborn Protection Industry Restraints
3 Maternal Pertussis Vaccine for Newborn Protection Market by Manufacturers
- 3.1 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Manufacturers (2021-2026)
- 3.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Manufacturers (2021-2026)
- 3.3 Global Maternal Pertussis Vaccine for Newborn Protection Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Maternal Pertussis Vaccine for Newborn Protection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Maternal Pertussis Vaccine for Newborn Protection Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Maternal Pertussis Vaccine for Newborn Protection Manufacturers, Product Type & Application
- 3.7 Global Maternal Pertussis Vaccine for Newborn Protection Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Maternal Pertussis Vaccine for Newborn Protection Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Maternal Pertussis Vaccine for Newborn Protection Players Market Share by Revenue in 2025
- 3.8.3 2025 Maternal Pertussis Vaccine for Newborn Protection Tier 1, Tier 2, and Tier 3
4 Maternal Pertussis Vaccine for Newborn Protection Market by Type
- 4.1 Maternal Pertussis Vaccine for Newborn Protection Type Introduction
- 4.1.1 Whole-cell Pertussis Vaccine
- 4.1.2 Acellular Pertussis Vaccine
- 4.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Type
- 4.2.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Type (2021-2032)
- 4.2.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Market Share by Type (2021-2032)
- 4.3 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Type
- 4.3.1 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Type (2021-2032)
- 4.3.3 Global Maternal Pertussis Vaccine for Newborn Protection Revenue Market Share by Type (2021-2032)
5 Maternal Pertussis Vaccine for Newborn Protection Market by Application
- 5.1 Maternal Pertussis Vaccine for Newborn Protection Application Introduction
- 5.1.1 Hospital
- 5.1.2 Centers for Disease Control and Prevention
- 5.1.3 Others
- 5.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Application
- 5.2.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Application (2021-2032)
- 5.2.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Market Share by Application (2021-2032)
- 5.3 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Application
- 5.3.1 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Application (2021-2032)
- 5.3.3 Global Maternal Pertussis Vaccine for Newborn Protection Revenue Market Share by Application (2021-2032)
6 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region
- 6.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region (2021-2032)
- 6.2.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region (2021-2026)
- 6.2.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Maternal Pertussis Vaccine for Newborn Protection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Maternal Pertussis Vaccine for Newborn Protection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Maternal Pertussis Vaccine for Newborn Protection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Maternal Pertussis Vaccine for Newborn Protection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Region
- 7.1 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Region
- 7.1.1 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Region (2021-2026)
- 7.1.3 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Region (2027-2032)
- 7.1.4 Global Maternal Pertussis Vaccine for Newborn Protection Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Maternal Pertussis Vaccine for Newborn Protection Revenue (2021-2032)
- 7.2.2 North America Maternal Pertussis Vaccine for Newborn Protection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Maternal Pertussis Vaccine for Newborn Protection Revenue (2021-2032)
- 7.3.2 Europe Maternal Pertussis Vaccine for Newborn Protection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Revenue (2021-2032)
- 7.4.2 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Maternal Pertussis Vaccine for Newborn Protection Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Maternal Pertussis Vaccine for Newborn Protection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Zhifei Biological
- 8.1.1 Zhifei Biological Company Information
- 8.1.2 Zhifei Biological Business Overview
- 8.1.3 Zhifei Biological Maternal Pertussis Vaccine for Newborn Protection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Zhifei Biological Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.1.5 Zhifei Biological Recent Developments
- 8.2 Walvax
- 8.2.1 Walvax Company Information
- 8.2.2 Walvax Business Overview
- 8.2.3 Walvax Maternal Pertussis Vaccine for Newborn Protection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Walvax Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.2.5 Walvax Recent Developments
- 8.3 Minhai Biological
- 8.3.1 Minhai Biological Company Information
- 8.3.2 Minhai Biological Business Overview
- 8.3.3 Minhai Biological Maternal Pertussis Vaccine for Newborn Protection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Minhai Biological Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.3.5 Minhai Biological Recent Developments
- 8.4 GlaxoSmithKline
- 8.4.1 GlaxoSmithKline Company Information
- 8.4.2 GlaxoSmithKline Business Overview
- 8.4.3 GlaxoSmithKline Maternal Pertussis Vaccine for Newborn Protection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 GlaxoSmithKline Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.4.5 GlaxoSmithKline Recent Developments
- 8.5 Sanofi Pasteur
- 8.5.1 Sanofi Pasteur Company Information
- 8.5.2 Sanofi Pasteur Business Overview
- 8.5.3 Sanofi Pasteur Maternal Pertussis Vaccine for Newborn Protection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Sanofi Pasteur Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.5.5 Sanofi Pasteur Recent Developments
- 8.6 Intravacc
- 8.6.1 Intravacc Company Information
- 8.6.2 Intravacc Business Overview
- 8.6.3 Intravacc Maternal Pertussis Vaccine for Newborn Protection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Intravacc Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
- 8.6.5 Intravacc Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Maternal Pertussis Vaccine for Newborn Protection Value Chain Analysis
- 9.1.1 Maternal Pertussis Vaccine for Newborn Protection Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Maternal Pertussis Vaccine for Newborn Protection Production Mode & Process
- 9.2 Maternal Pertussis Vaccine for Newborn Protection Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Maternal Pertussis Vaccine for Newborn Protection Distributors
- 9.2.3 Maternal Pertussis Vaccine for Newborn Protection Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst